Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) entered clinical practice as glucose-lowering agents, exerting their principal metabolic effects through glucose-dependent stimulation of insulin secretion, suppression of glucagon release, and deceleration of gastric emptying.[1] Early trials confirmed robust reductions in glycated hemoglobin (HbA1c)[2] and body weight,[3] establishing this drug class as a cornerstone therapy for type 2 diabetes mellitus (T2DM) and obesity. However, cardiovascular outcome trials (CVOTs),[4-12] uncovered a dimension of benefit that extends far beyond glycemic management. GLP-1 RAs consistently reduce major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, nonfatal myocardial infarction (MI), and nonfatal stroke, through mechanisms that operate partly independent of weight loss and glycemic improvement. This commentary examines the mechanistic basis, clinical evidence, and therapeutic implications of this evolving paradigm shift. GLP-1 receptors are expressed not only in pancreatic beta cells but also in vascular endothelium, cardiomyocytes, vascular smooth muscle cells, and immune cells, providing a biological basis for direct cardiovascular actions independent of glucose lowering.[13] GLP-1 RAs enhance phosphorylation and activation of endothelial nitric oxide synthase, increasing nitric oxide bioavailability, promoting vasodilation, and reducing arterial stiffness.[14] In patients with T2DM, exenatide improved flow-mediated dilation by 2%–3%, a validated surrogate of endothelial integrity.[15] GLP-1 RAs also reduce systolic blood pressure by 2–6 mmHg through natriuresis, reduced sympathetic tone, and improved vascular compliance effects confirmed across multiple CVOTs.[16] GLP-1 RAs suppress pro-inflammatory cytokines, including tumor necrosis factor-alpha, Interleukin-6, and interleukin-1 beta, while promoting macrophage polarization from the M1 (pro-inflammatory) to the M2 (anti-inflammatory) phenotype.[17] GLP-1 RAs reduced high-sensitivity C-reactive protein by 20%–30% in clinical trial settings, reflecting systemic anti-inflammatory activity.[18] Suppression of the NLRP3 inflammasome represents a mechanistically critical upstream effect, as this pathway drives atherogenesis, foam cell formation, and myocardial inflammation.[19] In ApoE-knockout murine models, liraglutide reduced atherosclerotic lesion area by approximately 30%, attenuating monocyte chemoattractant protein-1 expression and macrophage infiltration.[20] Semaglutide similarly attenuated plaque progression in low-density lipoprotein receptor-deficient mice through downregulation of pro-inflammatory chemokines.[21] By reducing matrix metalloproteinase-9 expression and inhibiting foam cell formation, GLP-1 RAs strengthen the fibrous cap and reduce plaque vulnerability to rupture – a mechanism directly relevant to acute coronary syndromes.[20] GLP-1 RAs reduce LDL cholesterol by 5%–10% and lower triglycerides while raising HDL cholesterol, through inhibition of hepatic very low-density lipoprotein production and activation of lipoprotein lipase.[22] These lipid-modulating actions complement their direct antiatherogenic vascular effects. Data from the Heart Protection Study demonstrated that a 33% reduction in LDL-C corresponded to a 31% decrease in composite cardiovascular endpoints among patients with T2DM.[23] The convergence of endothelial protection, anti-inflammatory activity, plaque stabilization, blood pressure reduction, and lipid modification creates a multi-target cardiovascular profile operating substantially beyond glucose and weight control. The LEADER trial enrolled 9,340 patients with T2DM at high cardiovascular risk. Liraglutide (1.8 mg once daily) reduced MACE by 13% versus placebo (heart rate [HR] 0.87; 95% confidence interval [CI] 0.78–0.97), driven by a 22% reduction in cardiovascular death (HR 0.78) and a 15% reduction in all-cause mortality (HR 0.85).[6] Weight loss averaged only 2–3 kg, and HbA1c declined by 0.4%, changes insufficient to fully account for the magnitude of MACE reduction, implicating direct pleiotropic mechanisms. Among 3297 patients with T2DM, subcutaneous semaglutide (0.5 or 1.0 mg once weekly) reduced MACE by 26% (HR 0.74; 95% CI 0.58–0.95).[7] The benefit was driven predominantly by a 39% reduction in nonfatal stroke (HR 0.61), distinguishing semaglutide’s cardiovascular profile from liraglutide. This trial’s 104-week duration and modest weight reduction (~4–6 kg) further decouple the cardiovascular benefit from substantial weight loss. REWIND uniquely enrolled 9,901 patients with T2DM across a broader cardiovascular risk spectrum – only 31% had established atherosclerotic disease. Dulaglutide (1.5 mg once weekly) reduced MACE by 12% (HR 0.88; 95% CI 0.79–0.99), with consistent reductions across MI, stroke, and cardiovascular death.[9] Among patients without prior cardiovascular events, the HR was 0.93, suggesting a signal toward primary prevention with important implications for earlier treatment initiation. The SELECT trial constitutes the most consequential paradigm-shifting evidence to date. Among 17,604 overweight or obese individuals without diabetes but with established cardiovascular disease, semaglutide 2.4 mg weekly reduced MACE by 20% (HR 0.80; 95% CI 0.72–0.90).[12] Mediation analyses demonstrated that weight loss explained only a portion of the MACE reduction, confirming the contribution of weight-independent mechanisms. This trial establishes GLP-1 RAs as cardiovascular drugs effective irrespective of diabetes status. A 2021 systematic review and meta-analysis of CVOTs encompassing 56,004 patients confirmed a 14% overall MACE reduction (HR 0.86; 95% CI 0.80–0.93) with GLP-1 RAs, alongside significant reductions in cardiovascular death, MI, stroke, and all-cause mortality.[24] The SELECT trial establishes that GLP-1 RAs reduce MACE in nondiabetic populations with obesity and established cardiovascular disease. The Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction (HFpEF) trial extended this frontier further: semaglutide 2.4 mg weekly improved heart failure symptoms and reduced heart failure hospitalizations (HR 0.79) in obese patients with HFpEF, irrespective of diabetes status but not powered for clinical outcomes.[25] This represents a meaningful advance in HFpEF, a syndrome for which pharmacotherapy has historically offered limited benefit. In the STEP-1 trial, semaglutide achieved 12%–15% weight reduction in nondiabetic obese individuals with attendant improvements in blood pressure, lipids, and inflammatory markers,[26] supporting integration of GLP-1 RAs into a cardiometabolic prevention framework spanning far beyond T2DM. Not all GLP-1 RAs demonstrate uniform cardiovascular benefit, and heterogeneity across trials suggests molecule-specific and population-dependent effects. Current American Diabetes Association Standards of Care recommend GLP-1 RAs with proven cardiovascular benefit as preferred agents in T2DM patients with established or high-risk cardiovascular disease, independent of baseline HbA1c.[27] Comparison with SGLT2 inhibitors provides essential therapeutic context. A 2019 meta-analysis demonstrated that GLP-1 RAs confer greater reductions in atherosclerotic events (MI and stroke), while SGLT2 inhibitors show greater benefit in reducing heart failure hospitalizations and renal disease progression.[28] Real-world data further suggest that the combination use of both drug classes reduces cardiovascular and renal events more than either agent alone in high-risk patients with T2DM.[29] Rather than competing, these agents offer complementary and synergistic cardiovascular protection [Figure 1].Figure 1: Integrated approach to cardiometabolic management. This figure illustrates the selection of therapy based on specific complications and comorbidities (left) and the synergistic cardiometabolic protection achieved through combined GLP-1 RA and SGLT2i therapy (right)Gastrointestinal adverse effects represent the most frequently reported tolerability concern with GLP-1 RAs. Nausea occurs in 25%–60% of patients, vomiting in 5%–15%, and diarrhea is also commonly reported. Although these symptoms are typically transient and self-limiting, they contribute to treatment discontinuation in 5%–15% of trial participants.[30] The intrinsic hypoglycemic risk of GLP-1 RAs is low, as their insulin-stimulating action is glucose-dependent. However, clinicians must exercise caution when co-prescribing GLP-1 RAs alongside insulin or sulfonylureas, which may increase hypoglycemic risk. In addition, rare cases of gallbladder disease, including cholelithiasis, have been reported with certain agents in this class.[31] Early observational data raised concerns regarding a possible association between GLP-1 RAs and pancreatitis or pancreatic cancer; however, these signals have not been corroborated by large-scale CVOTs nor by recent meta-analyses, despite a numerically marginal elevation in pancreatitis incidence.[24] In the absence of established biological causality, current clinical guidance nonetheless advises against the use of GLP-1 RAs in patients with a prior history of pancreatitis, reflecting a precautionary approach. Locally, injection-site reactions, particularly pruritus and erythema, represent an additional tolerability consideration, occurring most prominently with longer-acting formulations within this therapeutic class.[32] A notable safety signal emerged in SUSTAIN-6,[7] where semaglutide was associated with an increased risk of diabetic retinopathy complications, particularly among patients with preexisting retinopathy and poor baseline glycemic control. This finding is widely interpreted because of rapid glucose lowering rather than a direct deleterious retinal effect, consistent with the phenomenon previously observed with intensive insulin therapy. Results of preclinical studies demonstrated that GLP-1 receptor agonists induce thyroid C-cell tumors in a dose- and duration-dependent manner, although such tumors are exceptionally rare in clinical practice. Considering these findings, the FDA incorporated a precautionary warning regarding this potential risk into the approval labelling of all long-acting GLP-1 receptor agonists.[33] It should be noted that CVOTs differ in design, populations, and duration, with some agents demonstrating neutral effects, suggesting heterogeneity within the class. Cardiovascular benefit is not a uniform class effect. The ELIXA trial with lixisenatide demonstrated a neutral MACE outcome (HR 1.02; 95% CI 0.89–1.17),[4] and the EXSCEL trial with once-weekly exenatide did not achieve statistical superiority (HR 0.91; 95% CI 0.83–1.00).[5] The generalizability of recent findings, such as SELECT, is restricted to secondary prevention populations with obesity. Finally, real-world implementation is challenged by high cost, tolerability issues, and uncertain long-term adherence, which may attenuate population-level impact. GLP-1 RAs have undergone a fundamental reconceptualization: they are no longer glucose-lowering drugs with incidental cardiovascular benefit, but cardiovascular agents with powerful metabolic and weight-loss effects. Integrating these agents into a cardiovascular prevention framework, complementing statins, antihypertensives, and SGLT2 inhibitors, represents not incremental refinement but a genuine paradigm shift in cardiometabolic medicine.